Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | SCN4A | P35499 | 2/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | AOC2 | O75106 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17813019 | 0.87 | KDM4E (0.61) | KDM4ECYP1A2SCN4AADRB2ADRB1 | |
| SCHEMBL4334443 | 0.86 | ALDH1A1 (0.55) | KDM4ECYP1A2SCN4AADRB2ADRB1 | |
| SCHEMBL9120301 | 0.83 | KDM4E (0.58) | KDM4ECYP1A2SCN4AADRB2ADRB1 | |
| SCHEMBL29689978 | 0.83 | KDM4E (0.58) | KDM4ECYP1A2SCN4AADRB2ADRB1 | |
| SCHEMBL19121724 | 0.83 | HTR1B (0.53) | KDM4ECYP1A2SCN4AADRB2ADRB1 | |
| SCHEMBL8607298 | 0.83 | SCN4A (0.66) | KDM4ECYP1A2SCN4AADRB2ADRB1 | |
| SCHEMBL3629149 | 0.83 | KDM4E (0.68) | KDM4ECYP1A2SCN4AADRB2ADRB1 | |
| SCHEMBL18295381 | 0.83 | SCN4A (0.66) | KDM4ECYP1A2SCN4AADRB2ADRB1 | |
| SCHEMBL29641315 | 0.83 | SCN4A (0.66) | KDM4ECYP1A2SCN4AADRB2ADRB1 | |
| SCHEMBL11677012 | 0.82 | CYP1A2 (0.56) | KDM4ECYP1A2SCN4AADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4277591-A1 | ETHER COMPOUNDS AS VOLATILES FOR THE TREATMENT OF AMINO ACID BASED SUBSTRATES, SUCH AS SKIN AND HAIR | Momentive Performance Materials GmbH (DE) | 2023-11-22 | — | — | EP | claimed |
| WO-2022152742-A1 | ETHER COMPOUNDS AS VOLATILES FOR THE TREATMENT OF AMINO ACID BASED SUBSTRATES, SUCH AS SKIN AND HAIR | MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) | 2022-07-21 | — | — | WO | claimed |
| EP-4277591-A1 | ETHER COMPOUNDS AS VOLATILES FOR THE TREATMENT OF AMINO ACID BASED SUBSTRATES, SUCH AS SKIN AND HAIR | Momentive Performance Materials GmbH (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-11814388-B1 | Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers | FERRIS STATE UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2022152742-A1 | ETHER COMPOUNDS AS VOLATILES FOR THE TREATMENT OF AMINO ACID BASED SUBSTRATES, SUCH AS SKIN AND HAIR | MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) | 2022-07-21 | — | — | WO | disclosed |
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2020185928-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| EP-2729479-B1 | CATALYSTS | BOREALIS AG (AT) | 2017-09-06 | — | — | EP | disclosed |
| EP-1773125-B1 | 5-IODOTETRAZOLES | LANXESS DEUTSCHLAND GMBH (DE) | 2008-05-21 | — | — | EP | disclosed |
| US-20070259786-A1 | Herbicidal Composition | SYNGENTA CROP PROTECTION, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-7235699-B2 | Alkoxy-substituted indanes and the production thereof | SYMRISE GMBH & CO. KG (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235699-B2 | Alkoxy-substituted indanes and the production thereof | SYMRISE GMBH & CO. KG (DE) | 2007-06-26 | — | — | US | disclosed |
| US-6106999-A | SENSITIVITY TO GENERAL-PURPOSE VISIBLE LIGHT LASER, SO THAT HIGH-SPEED SCANNING EXPOSURE IS POSSIBLE BY LASER, AND EXTREMELY FINE HIGH RESOLUTION CAN BE OBTAINED; CAN BE USED FOR COATING OR PRINTING UNDER SAFELIGHT IRRADIATING CONDITIONS | MITSUI CHEMICALS (JP) | 2000-08-22 | — | — | US | disclosed |
| US-4837301-A | FROM ALKALI MTEAL SULFIDES AND AROMATIC DIHALOGEN COMPOUNDS; IMPROVED CORROSION RESISTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-06 | — | — | US | disclosed |
| EP-0275007-A2 | Process for the preparation of highly molecular, optionally branched polyarylene sulfides | BAYER AG (DE) | 1988-07-20 | — | — | EP | disclosed |
| US-4113782-A | CATALYTIC OXIDATION | AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | KDM4E 2621/4885CYP1A2 3438/4885SCN4A 80/4885 |
| US-20070259786-A1 | Herbicidal Composition | DDT, IDH2, ACHE | KDM4E 1547/4885CYP1A2 12/4885SCN4A 1825/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | KDM4E 2621/4885CYP1A2 3438/4885SCN4A 80/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | KDM4E 2621/4885CYP1A2 3438/4885SCN4A 80/4885 |
| US-11814388-B1 | Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers | AURKA, AURKC, AURKB | KDM4E 844/4885CYP1A2 3929/4885SCN4A 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.